• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure

    6/4/25 4:30:51 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email
    false 0001468929 0001468929 2025-06-04 2025-06-04 0001468929 NXGL:CommonStockParValue0.001Member 2025-06-04 2025-06-04 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2025-06-04 2025-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 4, 2025

     

    NEXGEL, INC.

     

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41173   26-4042544
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    2150 Cabot Boulevard West, Suite B

    Langhorne, Pennsylvania

      19067
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (215) 702-8550

     

    (Former name or former address, if changed since last report)

    Not Applicable

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
    Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On June 4, 2025, NexGel, Inc. began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.1.

     

    The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

      Description
         
    99.1   NexGel, Inc. Investor Presentation, dated June 2025.
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 4, 2025    
       
    NEXGEL, INC.
       
    By: /s/ Adam Levy
      Adam Levy
      Chief Executive Officer

     

     

     

    Get the next $NXGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    SEC Filings

    See more
    • NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NEXGEL, INC. (0001468929) (Filer)

      6/4/25 4:30:51 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by NexGel Inc

      10-Q - NEXGEL, INC. (0001468929) (Filer)

      5/13/25 5:00:29 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEXGEL, INC. (0001468929) (Filer)

      5/13/25 4:18:17 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on NexGel with a new price target

      Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

      2/25/22 9:17:01 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Levy Adam R. sold $2,220 worth of shares (1,000 units at $2.22), decreasing direct ownership by 0.27% to 368,284 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      6/2/25 8:00:07 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Levy Adam R. sold $2,575 worth of shares (1,000 units at $2.58), decreasing direct ownership by 0.27% to 369,284 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      5/20/25 8:00:04 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Henry Scott Robert sold $8,062 worth of shares (3,000 units at $2.69), decreasing direct ownership by 2% to 132,053 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      5/13/25 8:00:04 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NXGL
    Leadership Updates

    Live Leadership Updates

    See more

    $NXGL
    Financials

    Live finance-specific insights

    See more

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:14 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:12 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

      4 - NEXGEL, INC. (0001468929) (Issuer)

      11/22/24 4:54:08 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

      LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati

      1/2/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

      LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e

      10/4/24 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee

      LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee. "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment comm

      1/17/23 7:30:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports First Quarter 2025 Financial Results

      First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

      5/13/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023 Over 100% full year and fourth quarter revenue growth year-over-year for third consecutive year Company issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year LANGHORNE, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record

      3/24/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd

      LANGHORNE, Pa., May 21, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on Monday, June 2, 2025 from 1-9 p.m. CT. During the event Mr. Levy will participate in a fireside chat hosted by Scott Weis of Semco Capital. The Annual CEO Networking Event hosted by Semco Capital brings together a consortium of leading microcap companies with unique business m

      5/21/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL Reports First Quarter 2025 Financial Results

      First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

      5/13/25 4:05:00 PM ET
      $NXGL
      Medical/Dental Instruments
      Health Care
    • NEXGEL to Report First Quarter 2025 Financial Results on May 13th

      Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day. First Quarter 2025 Financial Results Conference CallDate: May 13, 2025Time: 4:30 P.M. ETLive Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (Internatio

      5/9/25 9:00:00 AM ET
      $NXGL
      Medical/Dental Instruments
      Health Care